A Network Medicine Approach to Investigating ME/CFS Pathogenesis in Severely Ill Patients: A Pilot Study

Li-Yuan Hung[1†], Chan-Shuo Wu[1†], Chia-Jung Chang[2], Peng Li[1], Kimberly Hicks[3], Becky Taurog[4], Joshua J Dibble[1], Braxton Morrison[1], Chimere L Smith[4], Ronald W Davis[2], Wenzhong Xiao[1]

[1] Computational Research Center for Complex Chronic Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA;

[2] ME/CFS Collaborative Research Center, Stanford University School of Medicine, Palo Alto, CA 94304, USA;

[3] Open Medicine Foundation;

[4] Patient Led Research Initiative.

[†]The authors contributed equally to this work.

Correspondence:
Corresponding Author
Wenzhong.Xiao@mgh.harvard.edu

Keywords: Network Medicine, ME/CFS, Chronic Fatigue Syndrome, Neuroimmunology, Neurodegenerative Diseases, Cognitive Disorders, PPI Network Analysis, Long COVID

Abstract

This pilot study harnessed the power of network medicine to unravel the complex pathogenesis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). By utilizing a network analysis on whole genome sequencing (WGS) data from the Severely Ill Patient Study (SIPS), we identified ME/CFS-associated proteins and delineated the corresponding network-level module, termed the SIPS disease module, together with its relevant pathways. This module demonstrated significant overlap with genes implicated in fatigue, cognitive disorders, and neurodegenerative diseases. Our pathway analysis revealed potential associations between ME/CFS and conditions such as COVID-19, Epstein-Barr virus (EBV) infection, neurodegenerative diseases, and pathways involved in cortisol synthesis and secretion, supporting the hypothesis that ME/CFS is a neuroimmune disorder. Additionally, our findings underscore a potential link between ME/CFS and estrogen signaling pathways, which may elucidate the higher prevalence of ME/CFS in females. These findings provide insights into the pathogenesis of ME/CFS from a network medicine perspective and highlight potential therapeutic targets. Further research is needed to validate these findings and explore their implications for improving diagnosis and treatment.

1   Introduction

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex and debilitating condition characterized by persistent fatigue, cognitive impairments, post-exertional malaise, and a variety of other symptoms that severely impact patients' quality of life (Cortes Rivera et al., 2019). Notably, the condition predominantly affects women (Lim et al., 2020). Despite extensive research, the etiology of ME/CFS remains elusive, and effective treatments are still lacking. Recent evidence suggests that neuroimmune dysfunction plays a crucial role in the pathogenesis of ME/CFS (Marshall-Gradisnik and Eaton-Fitch, 2022; Morris and Maes, 2013a, 2013b; Ryabkova et al., 2022).

Genetic factors are believed to contribute significantly to ME/CFS, with prior studies suggesting a genetic predisposition to the disease (Afari and Buchwald, 2003; Albright et al., 2011). However, the specific genes and pathways involved have not been fully elucidated (Dibble et al., 2020). This study employs a network medicine approach to investigate the genetic underpinnings of ME/CFS, focusing on its most severe manifestations.

Approximately 25% of ME/CFS patients are severely ill and are often housebound or bedridden (Feiden, 1990; Fennell et al., 1998; Pendergrast et al., 2016). Our research centers on the Severely Ill Patient Study (SIPS) cohort, which includes patients enduring the most severe symptoms of ME/CFS (Chang et al., 2021). These individuals suffer from profound fatigue, cognitive impairment, and a significantly reduced quality of life. Previous analyses of this cohort revealed unique sleep profiles, cognitive deficits, and markedly low morning cortisol levels. Additionally, parallels between ME/CFS and long COVID symptoms suggest common etiological pathways (Chang et al., 2021). The credibility of the SIPS cohort is reinforced by its validation by medical professionals, ensuring the authenticity and representativeness of the data.

The network medicine approach provides a sophisticated framework for understanding disease mechanisms at the molecular level. This paradigm introduces the concept of *disease modules*, interconnected subgraphs within the protein-protein interaction (PPI) network that represent the molecular facets of specific conditions. By examining these modules, researchers can predict disease relationships and elucidate the molecular mechanisms underlying complex diseases (Barabási et al., 2011; Menche et al., 2015; Sharma et al., 2015).

By harnessing the power of PPI network analysis and whole genome sequencing (WGS), we identified pathways potentially contributing to ME/CFS development. Our findings suggest significant involvement of the immune and neurological systems, indicating shared genetic underpinnings with these systems.

In summary, this study sheds light on the genetic landscape of ME/CFS, providing new insights and potentially paving the way for novel therapeutic interventions. Our findings, particularly those related to immune and neurological pathways, could reshape our understanding of ME/CFS and lead to more targeted treatment strategies.

2 Results

In the Severely Ill Patient Study (SIPS) (Chang et al., 2021), we investigated the medical conditions of 20 ME/CFS patients exhibiting severe symptoms, as previously documented. These individuals met the International Consensus Criteria for ME/CFS (ME-ICC) (Carruthers et al., 2011) and were confined to their homes, remaining sedentary and reclined for over 14 hours daily. Their SF-36 physical functioning scores and Karnofsky Performance Status Index (Karnofsky and Burchenal, 1949) scores were both below 70.

WGS was performed on the blood samples from the 20 SIPS patients, and high-confidence variants were filtered based on several criteria (see Methods), resulting in 2,798,019 variants for further analysis. Using the American College of Medical Genetics and Genomics (ACMG) criteria, we identified 103 pathogenic or likely pathogenic variants (Qiagen IVA). These were then compared to background population data, leading to the removal of 7 common SNVs. The remaining 96 variants were aggregated at the gene level (Table S1). Among them, 9 genes were found to affect at least 2 (10%) of the 20 patients (Figure 1, Table S1).

We examined the nine genes with recurrent variants in the SIPS patients (Figure 1), specifically *ACADL*, *BRCA1*, *CFTR*, *COX10*, *HABP2*, *MFRP*, *PCLO*, *PRKN*, and *ZFPM2*. Given the defining characteristic of cognitive abnormalities in SIPS patients, it was crucial to assess the relevance of these genes to their symptoms. Seven of the nine genes (77.8%) have previously been linked to cognitive impairment or neurological functions. For instance, *BRCA1* is involved in maintaining genomic stability and has implications in neurodegeneration and stress-induced senescence (Leung and Hazrati, 2021; Suberbielle et al., 2015). The *PRKN* gene is associated with Parkinson's disease, characterized by both motor and non-motor symptoms (Lücking et al., 2000). *CFTR*'s expression in the nervous system may influence mood, memory, energy balance, olfaction, motor function, respiration, and autonomic control of visceral organs (Reznikov, 2017). Mutations in the *COX10* gene, crucial for cellular respiration, have been linked to various peripheral neuropathy disorders (Fünfschilling et al., 2012; Kuroha et al., 2022). *MFRP* is tied to eye development, with mutations affecting retinal microglia (Kumari et al., 2022). *PCLO*, encoding the Piccolo protein essential for synaptic transmission, has mutations linked to pontocerebellar hypoplasia, a rare neurodegenerative disorder (Ackermann et al., 2019; Ahmed et al., 2015). *ZFPM2* is involved in the development of GABAergic neurons in specific brain regions (Morello et al., 2020).

Our results suggest a connection between the identified pathogenic variants and cognitive symptoms in the SIPS patients. While further studies are required to elucidate how these genes influence cognitive impairment in the SIPS patients, Figure 1 provides a valuable foundation for future investigations.

To investigate the genetic factors contributing to the onset and progression of ME/CFS in severely ill patients, we utilized a network-based approach that considers the interconnections between disease-related genes. This approach aims to identify and locate the SIPS disease module within the human PPI network and discern its interplay with other pathways or conditions. During the network

construction process, emphasis is placed on relevant genes, as disease-associated genes tend to
cluster together, forming interconnected subnetworks, while unrelated genes scatter randomly and
minimally influence the subnetwork's structure (Menche et al., 2015).

Applying the Disease Module Detection (DIAMOnD) algorithm (Ghiassian et al., 2015), we
successfully inferred the SIPS disease module by starting with a subgraph of seed genes derived from
96 pathogenic or likely pathogenic variants identified in the 20 SIPS patients (Table S1). Using this
set of seed genes as the input, the DIAMOnD algorithm identified the top 200 neighborhoods,
forming the SIPS disease module (for details, refer to Table S2). Within the disease module, we
noted a significant presence of genes related to fatigue and cognitive disorders. Using the disease-
gene association data from DisGeNET (Piñero et al., 2020) as a reference, genes linked to fatigue
exhibited a 3.94-fold enrichment (p-value: 1.3899e-14, cumulative hypergeometric test), while those
connected to cognitive disorders showed a 2.29-fold enrichment (p-value: 0.0005) (Figure 2A).
Furthermore, the SIPS disease module was found to intertwine with the six neurodegenerative
disease pathways in KEGG (Kanehisa et al., 2023) (Figure 2A, 2B), with enrichment ranging from
2.48 to 4.61 fold (Figure 2A).

Considering the widespread cognitive abnormalities in severely ill ME/CFS patients and the
unresolved questions surrounding the underlying mechanisms of these conditions, the intersection of
the SIPS disease module with neurological disease pathways is especially noteworthy.

In our subsequent analysis, we compared the SIPS disease module with the 70 disease modules
presented in the DIAMOnD publication (Ghiassian et al., 2015). These 70 diseases were classified
into 4 distinct categories based on their conceivable links to the hypothesized mechanisms of
ME/CFS (Marshall-Gradisnik and Eaton-Fitch, 2022). A fifth category, cancer, was incorporated as
an out-group for comparative purposes. Our findings revealed that certain diseases exhibited
similarities with the SIPS disease module, as depicted in Figure 3A. Notably, nearly half of the top
20 diseases showing the greatest resemblance were either entirely or partially neurological disorders.
These included conditions such as muscular dystrophies, basal ganglia diseases, spinocerebellar
degenerations, Charcot−Marie−Tooth disease, motor neuron disease, cerebrovascular disorders,
amyotrophic lateral sclerosis (ALS), and cerebellar ataxia. In contrast, cancer disease modules
showed minimal similarity to the SIPS disease module.

When visualizing the SIPS disease module alongside the 70 DIAMOnD disease modules in a
network diagram, it was evident that the SIPS module closely overlapped with modules related to
immune and neurological systems (Figure 3B). The predominance of immune and neurological
conditions among the five most similar diseases suggests that the SIPS disease module might share
underlying causes with these two systems.

Our initial analyses offer valuable insights into the genetic makeup of ME/CFS. However, to solidify
these findings, it is essential to cross-reference them with data from other ME/CFS cohorts. Thus, we

incorporated data from two additional ME/CFS cohorts to enhance the SIPS disease module. The gene sets for these two cohorts were sourced from two distinct research studies:

1. The 23andMe Cohort: Based on a study published in Frontiers in Pediatrics (Perez et al., 2019a), we selected genes containing the 50 most commonly observed SNPs from gene regions in their ME/CFS cohort.
2. The UK-Nor Cohort: Using findings from a study published in Brain, Behavior, and Immunity (Hajdarevic et al., 2022), we focused on the genes proximate to their top 50 candidate variants (as detailed in the Method section).

Notably, the initial gene sets from these studies had little overlap with the SIPS seed gene set. However, as the initial gene sets expanded into disease modules, the SIPS disease module overlapped with other ME/CFS disease modules by approximately 40% (Table S3). This degree of overlap is unlikely to occur when overlapping the SIPS disease module with disease modules from random initial seeds (Figure S1).

Subsequently, we created a network representation for these three disease modules. As a reference point, we also constructed a disease module from a depressive disorder cohort (Howard et al., 2019). The disease modules from the other two ME/CFS cohorts appear to intertwine with the SIPS disease module (Figure 4A). In contrast, the depression disease module shows minimal overlap with the ME/CFS disease modules (Figure 4A). These observations suggest the possibility of shared genetic factors contributing to ME/CFS across different cohorts, and the SIPS disease module may represent a core set of genes implicated in the pathogenesis of ME/CFS.

This finding is particularly significant in addressing the long-standing stigma surrounding ME/CFS, which has often been misdiagnosed as merely a form of depression. Such misdiagnoses have led to inadequate treatment and lack of proper medical support for ME/CFS patients. The clear distinction between the genetic underpinnings of ME/CFS and depressive disorders underscores the necessity of recognizing ME/CFS as a distinct neuroimmune condition. By elucidating these differences, our study advocates for more accurate diagnosis and targeted therapeutic approaches for ME/CFS, moving away from the erroneous conflation with depression.

To uncover shared biological components among ME/CFS disease modules, we conducted a multi-gene set analysis using Metascape (Zhou et al., 2019). The results indicated that several pathways, including those related to COVID-19, Epstein-Barr virus (EBV) infection, antigen processing and presentation, and the MAPK signaling pathway, are likely associated with ME/CFS. The top 10 biological pathway clusters linked to ME/CFS disease modules are presented in Table 1. Given the well-documented association of ME/CFS with post-viral syndromes and the increasing similarities observed between Long COVID and ME/CFS, these findings are particularly noteworthy (Komaroff and Lipkin, 2023; Ryabkova et al., 2022; Spudich and Nath, 2022). Viral infections, including EBV, have been suggested as potential triggers for ME/CFS (Deumer et al., 2021). Notably, signal impairments in the MAPK pathway in natural killer (NK) cells have been previously reported in ME/CFS patients (Chacko et al., 2016; Huth et al., 2016). Other identified pathways related to various neurodegenerative disorders and thyroid hormone signaling have also been previously

associated with ME/CFS (Cortes Rivera et al., 2019; Marshall-Gradisnik and Eaton-Fitch, 2022). Interestingly, while not within the top 10 pathway clusters, the cortisol synthesis and secretion pathway was also enriched (Figure S2). This is particularly noteworthy as alterations in diurnal salivary cortisol rhythm were observed in the SIPS patients in our previous study (Chang et al., 2021).

On the other hand, the largest intra-cluster network component identified in the multi-gene set analysis was associated with immune response pathways related to infections, such as EBV infection, cytokine signaling, positive regulation of immune response, TNF-alpha/NF-kappa B signaling, and antigen processing and presentation (Figure 4B). The network primarily focused on EBV infection and cytokine signaling, which are known to be connected to ME/CFS (Ariza, 2021; Broderick et al., 2010; Maes et al., 2022). These findings further emphasize the potential role of immune dysregulation in the pathogenesis of this disease.

3   Methods

3.1   Whole genome sequencing (WGS) data generation

WGS was performed for the 20 SIPS ME/CFS patients. Blood samples were obtained from these patients for genomic DNA extraction. The extracted DNA samples were then sequenced on an Illumina NextSeq 500 platform using a 150-bp paired-end sequencing kit.

3.2   Read mapping and variant calling

For each sample, 150-bp paired-end reads were aligned to the human reference genome hg19 using Isaac Genome Alignment Software (Isaac-04.16.09.24). Variant calling was performed using Strelka2 Germline Variant Caller (2.7.1), Manta Structural Variant Caller (1.0.2), and Canvas CNV Caller (1.19.1).

3.3   Variant filtering

High-confidence variants were derived by applying a series of filters as follows:
1.   Variants had to be supported by reads from both strands.
2.   Conflicting variants (i.e., multiple types of variants were called at the same position) were excluded.
3.   Variants located within repetitive regions were excluded.
4.   Variants in the proximity of miscalls were removed to eliminate sequencing errors in specific regions.
5.   To reduce miscalls resulting from in-vitro contaminations or other systematic errors, a reasonable variant must have at least one homozygous sample in which both alleles are consistent with the reference.

In total, 2,798,019 high-confidence variants passed these five filters and were subsequently used in the following variant analysis.

3.4   Variant analysis

237 The high-confidence variants were uploaded to QIAGEN's Ingenuity Variant Analysis (IVA)
238 platform to identify ME/CFS-associated variants. The variant frequencies were compared with
239 background population frequency data from the Exome Aggregation Consortium (ExAC), 1000
240 Genomes Project, and the Genome Aggregation Database (gnomAD).
241
Using the ACMG criteria for the interpretation of sequence variants, we identified a total of 103
variants as *Pathogenic* or *Likely Pathogenic*. To rule out sporadic findings from variants not yet
included in these background databases, we further compared the frequencies of these variants with
the Kaviar database, the aforementioned background population data, and the Allele Frequency
Community (AFC; http://www.allelefrequencycommunity.com), as well as the WGS data of 20
randomly selected individuals from the Harvard Personal Genome Project (PGP). Seven of the 103
variants were removed because they had an odds ratio of less than 5 in any of these comparisons. The
resulting 96 variants (103-7) were aggregated to 93 genes, with 9 genes identified that affect at least
2 (or 10%) out of the 20 of the patients.

251 3.5 Network analysis

The disease module represents a network that expands from an initial set of genes. In this study, we
collected three distinct gene sets. The SIPS gene set served as our primary gene set, while the other
two sets were employed for refining or validating our disease module.
1.   The SIPS Gene Set: Derived from the SIPS data, this set was constructed from the 96 identified
variants, encompassing 93 genes that house these variants.
2.   23andMe Gene Set: This set was retrieved from the work of Perez et al. (Perez et al., 2019b),
who reported 46 genes associated with ME/CFS. These genes were extracted from the top 50
SNPs frequently reported in their ME/CFS cohort, each with C-scores exceeding 10. The
23andMe chip versions 4 (~570 k SNPs; prior to August 2017) and version 5 (~640 k SNPs;
after August 2017) were used.
3.   UK-Nor Gene Set: Based on Hajdarevic et al.'s study (Hajdarevic et al., 2022), this set was
derived from the top 50 variants reported in their Supplementary Table 7. Specifically, these
variants were either identified in the overlapping segments of two ME/CFS cohorts or exhibited
the lowest p-values in their GWAS analysis. Genes situated within a 500K base pair radius of
these variants' linkage disequilibrium (LD) block (with $r^2 \geq 0.5$, as determined by the LDproxy
function in LDLink) were chosen to represent this gene set.

268 4   Discussion

269 ME/CFS remains a poorly understood disease, despite its significant impact on patients' quality of
270 life. Our study, focusing on severely ill ME/CFS patients, provides valuable insights into potential
271 genetic factors and pathways that may contribute to the development of this disease.
272
273 Using a network-based approach, we identified several genes and pathways potentially involved in
274 the pathogenesis of ME/CFS, intersecting with the SIPS disease module. This module represents a
275 network implicated in ME/CFS pathogenesis and overlaps with pathways associated with
276 neurological diseases, which is particularly noteworthy given the prevalence of cognitive

abnormalities in severely ill ME/CFS patients. Moreover, the recurring DNA variants found in genes linked to cognitive and neurological functions suggest a strong genetic basis for the cognitive irregularities observed in SIPS patients. The overlap of the SIPS disease module with other disease modules related to the immune and neurological systems further supports the hypothesis that ME/CFS is a neuroimmune disorder.

Our ME/CFS disease modules exhibit a notable enrichment of pathway related to both COVID-19 and EBV infection (Table 1). Recent reports suggest that COVID-19 could potentially reactivate EBV, a virus long suspected to play a significant role in the development of ME/CFS (Gold et al., 2021). Interestingly, many symptoms associated with Long COVID are also common in ME/CFS (Komaroff and Lipkin, 2023). This overlap could potentially be linked to the reactivation of EBV in COVID-19 patients. Consequently, inflammation-induced reactivation of EBV may contribute to some of the symptoms observed in long COVID.

Our analysis also revealed a connection between ME/CFS and estrogen signaling pathways (Table 1). This finding aligns with Perez et al.'s study conducted on the 23andMe cohort, which proposed that certain identified SNPs might participate in hormone-related pathways, including estrogen signaling (Perez et al., 2019a). Given that estrogen is known to regulate innate immune cells and signaling pathways, its potential influence on the pathophysiology of ME/CFS cannot be overlooked (Thomas et al., 2022). This could provide insights into the observed predominance of ME/CFS in females.

It is noteworthy that among the original 103 variants identified in the severely ill patients, the most prevalent is rs35767802 on the *ADAMTSL2* gene. Although this variant has >12% allele frequency according to AFC population frequency, it was present in at least one allele in 45% (9/20) of the severely affected patients. The *ADAMTSL2* gene is part of the ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family, which plays a crucial role in the degradation of the extracellular matrix and has been linked to various human genetic disorders (Le Goff and Cormier-Daire, 2011). Notably, *ADAMTSL2* is associated with Type VIIC Ehlers–Danlos syndrome (EDS), with a mutation in *ADAMTSL2* recently identified in EDS patients (Desai et al., 2016). There may be a comorbidity between EDS and ME/CFS, as joint hypermobility—a characteristic of EDS— is frequently observed in ME/CFS patients (Eccles et al., 2021).

In addition, several biological pathways were exclusively identified in the SIPS disease module, as listed in Table S4. These pathways could potentially provide insights into the exacerbation of ME/CFS. However, we found no established connections between these pathways and ME/CFS. Pathways lacking cross-cohort validation, such as these, carry a high degree of uncertainty and may arise from methodological limitations. Therefore, further validation is needed to confirm these connections.

Overall, this study offers novel insights into the genetic factors that may contribute to severe ME/CFS, identifying several pathways potentially associated with the condition. The discovery of the SIPS disease module and its associated pathways provides a valuable foundation for future research,

potentially laying the groundwork for more effective treatments for this debilitating condition.
However, these findings are preliminary and, like previous studies, have limitations that necessitate
further validation. The accuracy of our findings relies on the current state of the ACMG criteria for
variant annotation, which may not be comprehensive. Moreover, while the DIAMOnD algorithm is
widely used, its effectiveness depends on the completeness and accuracy of the underlying human
PPI network data. The potential implications of these findings for the diagnosis and treatment of
severe ME/CFS also need to be explored. Future studies should aim to replicate our findings in larger
cohorts and to further investigate the potential role of immune and neurological pathways in severe
ME/CFS.

5 Author Contributions

329 WZX and LYH conceived and designed the study. WZX and RWD supervised the project. LYH,
330 CSW, and CJC collected the datasets. LYH, CSW, and CJC performed the data analysis and
331 conducted the statistical analysis. PL, KH, BT, JJD, BM, and CLM contributed to the interpretation
332 of the results. CSW and LYH drafted the manuscript. CSW, LYH, and WZX revised the manuscript.
333 All authors read and approved the final manuscript.

6 Funding

335 This work was supported by grants from Open Medicine Foundation and Patient Led Research
336 Collaboration (WX).

7 Acknowledgments

338 We would also like to express our sincere gratitude to each of the severely ill patients who
339 participated in this study.

8 References

Ackermann, F., Schink, K.O., Bruns, C., Izsvák, Z., Hamra, F.K., Rosenmund, C., Garner, C.C.,
2019. Critical role for Piccolo in synaptic vesicle retrieval. eLife 8, e46629.
https://doi.org/10.7554/eLife.46629
Afari, N., Buchwald, D., 2003. Chronic fatigue syndrome: a review. Am. J. Psychiatry 160, 221–236.
https://doi.org/10.1176/appi.ajp.160.2.221
Ahmed, M.Y., Chioza, B.A., Rajab, A., Schmitz-Abe, K., Al-Khayat, A., Al-Turki, S., Baple, E.L.,
Patton, M.A., Al-Memar, A.Y., Hurles, M.E., Partlow, J.N., Hill, R.S., Evrony, G.D.,
Servattalab, S., Markianos, K., Walsh, C.A., Crosby, A.H., Mochida, G.H., 2015. Loss of
PCLO function underlies pontocerebellar hypoplasia type III. Neurology 84, 1745–1750.
https://doi.org/10.1212/WNL.0000000000001523
Albright, F., Light, K., Light, A., Bateman, L., Cannon-Albright, L.A., 2011. Evidence for a heritable
predisposition to Chronic Fatigue Syndrome. BMC Neurol. 11, 62.
https://doi.org/10.1186/1471-2377-11-62
Ariza, M.E., 2021. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Human
Herpesviruses Are Back! Biomolecules 11, 185. https://doi.org/10.3390/biom11020185
Barabási, A.-L., Gulbahce, N., Loscalzo, J., 2011. Network medicine: a network-based approach to
human disease. Nat. Rev. Genet. 12, 56–68. https://doi.org/10.1038/nrg2918
Baron, J. A., Johnson, C. S., Schor, M. A., Olley, D., Nickel, L., Felix, V., Munro, J. B., Bello, S. M.,

359   Bearer, C., Lichenstein, R., Bisordi, K., Koka, R., Greene, C., Schriml, L. M., 2024. The DO-
360   KB Knowledgebase: a 20-year journey developing the disease open science ecosystem.
361   Nucleic Acids Res. 52(D1):D1305-D1314. https://doi.org/10.1093/nar/gkad1051
362 Broderick, G., Fuite, J., Kreitz, A., Vernon, S. D., Klimas, N., Fletcher, M. A., 2010. A formal
363   analysis of cytokine networks in chronic fatigue syndrome. Brain. Behav. Immun. 24(7).
364   https://doi.org/10.1016/j.bbi.2010.04.012
365 Carruthers, B.M., van de Sande, M.I., De Meirleir, K.L., Klimas, N.G., Broderick, G., Mitchell, T.,
366   Staines, D., Powles, A.C.P., Speight, N., Vallings, R., Bateman, L., Baumgarten-Austrheim,
367   B., Bell, D.S., Carlo-Stella, N., Chia, J., Darragh, A., Jo, D., Lewis, D., Light, A.R., Marshall-
368   Gradisbik, S., Mena, I., Mikovits, J.A., Murovska, M., Pall, M.L., Stevens, S., 2011. Myalgic
369   Encephalomyelitis: International Consensus Criteria. J. Intern. Med. 270(4):327-38.
370   https://doi.org/10.1111/j.1365-2796.2011.02428.x
371 Chacko, A., Staines, D.R., Johnston, S.C., Marshall-Gradisnik, S.M., 2016. Dysregulation of Protein
372   Kinase Gene Expression in NK Cells from Chronic Fatigue Syndrome/Myalgic
373   Encephalomyelitis Patients. Gene Regul. Syst. Biol. 10, 85–93.
374   https://doi.org/10.4137/GRSB.S40036
375 Chang, C.-J., Hung, L.-Y., Kogelnik, A.M., Kaufman, D., Aiyar, R.S., Chu, A.M., Wilhelmy, J., Li,
376   P., Tannenbaum, L., Xiao, W., Davis, R.W., 2021. A Comprehensive Examination of
377   Severely Ill ME/CFS Patients. Healthc. Basel Switz. 9, 1290.
378   https://doi.org/10.3390/healthcare9101290
379 Cortes Rivera, M., Mastronardi, C., Silva-Aldana, C.T., Arcos-Burgos, M., Lidbury, B.A., 2019.
380   Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review. Diagn.
381   Basel Switz. 9, 91. https://doi.org/10.3390/diagnostics9030091
382 Desai, A., Connolly, J.J., March, M., Hou, C., Chiavacci, R., Kim, C., Lyon, G., Hadley, D.,
383   Hakonarson, H., 2016. Systematic data-querying of large pediatric biorepository identifies
384   novel Ehlers-Danlos Syndrome variant. BMC Musculoskelet. Disord. 17, 80.
385   https://doi.org/10.1186/s12891-016-0936-8
386 Deumer, U.-S., Varesi, A., Floris, V., Savioli, G., Mantovani, E., López-Carrasco, P., Rosati, G.M.,
387   Prasad, S., Ricevuti, G., 2021. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
388   (ME/CFS): An Overview. J. Clin. Med. 10, 4786. https://doi.org/10.3390/jcm10204786
389 Dibble, J.J., McGrath, S.J., Ponting, C.P., 2020. Genetic risk factors of ME/CFS: a critical review.
390   Hum. Mol. Genet. 29, R117–R124. https://doi.org/10.1093/hmg/ddaa169
391 Eccles, J.A., Thompson, B., Themelis, K., Amato, M.L., Stocks, R., Pound, A., Jones, A.-M.,
392   Cipinova, Z., Shah-Goodwin, L., Timeyin, J., Thompson, C.R., Batty, T., Harrison, N.A.,
393   Critchley, H.D., Davies, K.A., 2021. Beyond bones: The relevance of variants of connective
394   tissue (hypermobility) to fibromyalgia, ME/CFS and controversies surrounding diagnostic
395   classification: an observational study. Clin. Med. Lond. Engl. 21, 53–58.
396   https://doi.org/10.7861/clinmed.2020-0743
397 Feiden, K., 1990. Hope and Help for Chronic Fatigue Syndrome: The Official Guide of the
398   CFS/CFIDS Network, 1st edition. ed. Simon & Schuster, New York.
399 Fennell, P.A., Jason, L.A., Klein, S.M., 1998. Capturing the Different Phases of the CFS Illness.
400   CFIDS Chron. 11, 13–16.
401 Fünfschilling, U., Supplie, L.M., Mahad, D., Boretius, S., Saab, A.S., Edgar, J., Brinkmann, B.G.,
402   Kassmann, C.M., Tzvetanova, I.D., Möbius, W., Diaz, F., Meijer, D., Suter, U., Hamprecht,
403   B., Sereda, M.W., Moraes, C.T., Frahm, J., Goebbels, S., Nave, K.-A., 2012. Glycolytic
404   oligodendrocytes maintain myelin and long-term axonal integrity. Nature 485, 517–521.
405   https://doi.org/10.1038/nature11007
406 Ghiassian, S.D., Menche, J., Barabási, A.-L., 2015. A DIseAse MOdule Detection (DIAMOnD)
407   algorithm derived from a systematic analysis of connectivity patterns of disease proteins in

408   the human interactome. PLoS Comput. Biol. 11, e1004120.
409    https://doi.org/10.1371/journal.pcbi.1004120
410 Gold, J.E., Okyay, R.A., Licht, W.E., Hurley, D.J., 2021. Investigation of Long COVID Prevalence
411    and Its Relationship to Epstein-Barr Virus Reactivation. Pathog. Basel Switz. 10, 763.
412    https://doi.org/10.3390/pathogens10060763
413 Hajdarevic, R., Lande, A., Mehlsen, J., Rydland, A., Sosa, D.D., Strand, E.B., Mella, O., Pociot, F.,
414    Fluge, Ø., Lie, B.A., Viken, M.K., 2022. Genetic association study in myalgic
415    encephalomyelitis/chronic fatigue syndrome (ME/CFS) identifies several potential risk loci.
416    Brain. Behav. Immun. 102, 362–369. https://doi.org/10.1016/j.bbi.2022.03.010
417 Howard, D.M., Adams, M.J., Clarke, T.-K., Hafferty, J.D., Gibson, J., Shirali, M., Coleman, J.R.I.,
418    Hagenaars, S.P., Ward, J., Wigmore, E.M., Alloza, C., Shen, X., Barbu, M.C., Xu, E.Y.,
419    Whalley, H.C., Marioni, R.E., Porteous, D.J., Davies, G., Deary, I.J., Hemani, G., Berger, K.,
420    Teismann, H., Rawal, R., Arolt, V., Baune, B.T., Dannlowski, U., Domschke, K., Tian, C.,
421    Hinds, D.A., Trzaskowski, M., Byrne, E.M., Ripke, S., Smith, D.J., Sullivan, P.F., Wray,
422    N.R., Breen, G., Lewis, C.M., McIntosh, A.M., 2019. Genome-wide meta-analysis of
423    depression identifies 102 independent variants and highlights the importance of the prefrontal
424    brain regions. Nat. Neurosci. 22, 343–352. https://doi.org/10.1038/s41593-018-0326-7
425 Huth, T.K., Staines, D., Marshall-Gradisnik, S. 2016. ERK1/2, MEK1/2 and p38 downstream
426    signalling molecules impaired in $CD56^{dim}CD16^{+}$ and $CD56^{bright}CD16^{dim/-}$ natural killer cells
427    in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. J. Transl. Med. 14, 97.
428    https://doi.org/10.1186/s12967-016-0859-z
429 Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M., Ishiguro-Watanabe, M., 2023. KEGG for
430    taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587–D592.
431    https://doi.org/10.1093/nar/gkac963
432 Karnofsky, D.A., Burchenal, J.H., 1949. The clinical evaluation of chemotherapeutic agents in
433    cancer, in: MacLeod, C.M. (Ed.), Evaluation of Chemotherapeutic Agents. Columbia
434    University Press, New York, pp. 191–205.
435 Komaroff, A.L., Lipkin, W.I., 2023. ME/CFS and Long COVID share similar symptoms and
436    biological abnormalities: road map to the literature. Front. Med. 10.
437 Kumari, A., Ayala-Ramirez, R., Zenteno, J.C., Huffman, K., Sasik, R., Ayyagari, R., Borooah, S.,
438    2022. Single cell RNA sequencing confirms retinal microglia activation associated with early
439    onset retinal degeneration. Sci. Rep. 12, 15273. https://doi.org/10.1038/s41598-022-19351-w
440 Kuroha, Y., Ishiguro, T., Tada, M., Hara, N., Murayama, K., Kawachi, I., Kasuga, K., Miyashita, A.,
441    Hasegawa, A., Takahashi, T., Matsubara, N., Onodera, O., Kakita, A., Koike, R., Ikeuchi, T.,
442    2022. Biallelic COX10 Mutations and PMP22 Deletion in a Family With Leigh Syndrome
443    and Hereditary Neuropathy With Liability to Pressure Palsy. Neurol. Genet. 8.
444    https://doi.org/10.1212/NXG.0000000000200030
445 Le Goff, C., Cormier-Daire, V., 2011. The ADAMTS(L) family and human genetic disorders. Hum.
446    Mol. Genet. 20, R163-167. https://doi.org/10.1093/hmg/ddr361
447 Leung, E., Hazrati, L.-N., 2021. Breast cancer type 1 and neurodegeneration: consequences of
448    deficient DNA repair. Brain Commun. 3, fcab117.
449    https://doi.org/10.1093/braincomms/fcab117
450 Lim, E.-J., Ahn, Y.-C., Jang, E.-S., Lee, S.-W., Lee, S.-H., Son, C.-G., 2020. Systematic review and
451    meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis
452    (CFS/ME). J. Transl. Med. 18, 100. https://doi.org/10.1186/s12967-020-02269-0
453 Lücking, C.B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B.S.,
454    Meco, G., Denèfle, P., Wood, N.W., Agid, Y., Nicholl, D., Breteler, M.M.B., Oostra, B.A.,
455    De Mari, M., Marconi, R., Filla, A., Bonnet, A.-M., Broussolle, E., Pollak, P., Rascol, O.,
456    Rosier, M., Arnould, A., Brice, A., 2000. Association between Early-Onset Parkinson's

Disease and Mutations in the Parkin Gene. N. Engl. J. Med. 342, 1560–1567. https://doi.org/10.1056/NEJM200005253422103

Maes, M., Kubera, M., Kotańska, M., 2022. Aberrations in the Cross-Talks Among Redox, Nuclear Factor-κB, and Wnt/β-Catenin Pathway Signaling Underpin Myalgic Encephalomyelitis and Chronic Fatigue Syndrome. Front. Psychiatry 13, 822382. https://doi.org/10.3389/fpsyt.2022.822382

Marshall-Gradisnik, S., Eaton-Fitch, N., 2022. Understanding myalgic encephalomyelitis. Science 377, 1150–1151. https://doi.org/10.1126/science.abo1261

Menche, J., Sharma, A., Kitsak, M., Ghiassian, S., Vidal, M., Loscalzo, J., Barabási, A.-L., 2015. Uncovering disease-disease relationships through the incomplete human interactome. Science 347, 1257601. https://doi.org/10.1126/science.1257601

Morello, F., Borshagovski, D., Survila, M., Tikker, L., Sadik-Ogli, S., Kirjavainen, A., Estartús, N., Knaapi, L., Lathi, L., Törönen, P., Mazutis, L., Delogu, A., Salminen, M., Achim, K., & Partanen, J., 2020. Molecular Fingerprint and Developmental Regulation of the Tegmental GABAergic and Glutamatergic Neurons Derived from the Anterior Hindbrain. Cell Rep. 33(2), 108268. https://doi.org/10.1016/j.celrep.2020.108268

Morris, G., Maes, M., 2013a. A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome. Metab. Brain Dis. 28, 523–540. https://doi.org/10.1007/s11011-012-9324-8

Morris, G., Maes, M., 2013b. Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med. 11, 205. https://doi.org/10.1186/1741-7015-11-205

Pendergrast, T., Brown, A., Sunnquist, M., Jantke, R., Newton, J.L., Strand, E.B., Jason, L.A., 2016. Housebound versus nonhousebound patients with myalgic encephalomyelitis and chronic fatigue syndrome. Chronic Illn. 12, 292–307. https://doi.org/10.1177/1742395316644770

Perez, M., Jaundoo, R., Hilton, K., Del Alamo, A., Gemayel, K., Klimas, N.G., Craddock, T.J.A., Nathanson, L., 2019a. Genetic Predisposition for Immune System, Hormone, and Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study. Front. Pediatr. 7, 206. https://doi.org/10.3389/fped.2019.00206

Perez, M., Jaundoo, R., Hilton, K., Del Alamo, A., Gemayel, K., Klimas, N.G., Craddock, T.J.A., Nathanson, L., 2019b. Genetic Predisposition for Immune System, Hormone, and Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study. Front. Pediatr. 7.

Piñero, J., Ramírez-Anguita, J.M., Saüch-Pitarch, J., Ronzano, F., Centeno, E., Sanz, F., Furlong, L.I., 2020. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 48, D845–D855. https://doi.org/10.1093/nar/gkz1021

Reznikov, L.R., 2017. Cystic Fibrosis and the Nervous System. Chest 151, 1147–1155. https://doi.org/10.1016/j.chest.2016.11.009

Ryabkova, V.A., Gavrilova, N.Y., Fedotkina, T.V., Churilov, L.P., Shoenfeld, Y., 2022. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post-COVID Syndrome: A Common Neuroimmune Ground? Diagn. Basel Switz. 13, 66. https://doi.org/10.3390/diagnostics13010066

Sharma, A., Menche, J., Huang, C.C., Ort, T., Zhou, X., Kitsak, M., Sahni, N., Thibault, D., Voung, L., Guo, F., Ghiassian, S.D., Gulbahce, N., Baribaud, F., Tocker, J., Dobrin, R., Barnathan, E., Liu, H., Panettieri, R.A., Tantisira, K.G., Qiu, W., Raby, B.A., Silverman, E.K., Vidal, M., Weiss, S.T., Barabási, A.-L., 2015. A disease module in the interactome explains disease heterogeneity, drug response and captures novel pathways and genes in asthma. Hum. Mol. Genet. 24, 3005–3020. https://doi.org/10.1093/hmg/ddv001

Spudich, S., Nath, A., 2022. Nervous system consequences of COVID-19. Science 375, 267–269.

https://doi.org/10.1126/science.abm2052
Suberbielle, E., Djukic, B., Evans, M., Kim, D.H., Taneja, P., Wang, X., Finucane, M., Knox, J., Ho,
K., Devidze, N., Masliah, E., Mucke, L., 2015. DNA repair factor BRCA1 depletion occurs in
Alzheimer brains and impairs cognitive function in mice. Nat. Commun. 6, 8897.
https://doi.org/10.1038/ncomms9897
Thomas, N., Gurvich, C., Huang, K., Gooley, P.R., Armstrong, C.W., 2022. The underlying sex
differences in neuroendocrine adaptations relevant to Myalgic Encephalomyelitis Chronic
Fatigue Syndrome. Front. Neuroendocrinol. 66, 100995.
https://doi.org/10.1016/j.yfrne.2022.100995
Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C.,
Chanda, S.K., 2019. Metascape provides a biologist-oriented resource for the analysis of
systems-level datasets. Nat. Commun. 10, 1523. https://doi.org/10.1038/s41467-019-09234-6

9   Tables

Table 1. Top 10 biological pathway clusters linked to ME/CFS disease modules.

Description	# Overlapping genes	LogP	Enrichment	Log(q-value)
Coronavirus disease - COVID-19	92	-90.34	18.14	-87.79
Epstein-Barr virus infection	44	-30.26	9.97	-28.19
Antigen processing and presentation	21	-25.59	32.70	-23.89
MAPK signaling pathway	38	-17.83	5.91	-16.18
Hepatitis B	29	-17.63	8.19	-16.03
Pathways of neurodegeneration - multiple diseases	42	-13.63	4.04	-12.43
Prion disease	33	-14.69	5.53	-13.32
Parkinson disease	29	-11.83	4.99	-10.82
Huntington disease	28	-9.64	4.19	-8.81
Alzheimer disease	30	-8.64	3.57	-7.87
Spinocerebellar ataxia	17	-7.77	5.44	-7.06
Amyotrophic lateral sclerosis	27	-7.37	3.39	-6.71
Diabetic cardiomyopathy	28	-14.01	6.31	-12.77
Thyroid hormone signaling pathway	20	-11.68	7.56	-10.69
Tight junction	15	-10.92	10.78	-9.82
Estrogen signaling pathway	19	-9.70	6.30	-8.85

10 Figures

%Alleles	%Individuals	P01	P02	P03	P04	P05	P06	P07	P08	P09	P10	P11	P12	P13	P14	P15	P16	P17	P18	P19	P20	Gene
5.0%	10%			frameshift															frameshift			ACADL
7.5%	15%												frameshift					frameshift	frameshift			BRCA1
5.0%	10%		in-frame					in-frame														CFTR
5.0%	10%																				missense	COX10
5.0%	10%				missense										missense							HABP2
17.5%	35%		frameshift	frameshift		frameshift				frameshift	frameshift		frameshift					frameshift				MFRP
5.0%	10%							in-frame							in-frame							PCLO
7.5%	15%								missense						stop gain			missense				PRKN
5.0%	10%									missense										missense		ZFPM2

Legend: missense, stop gain, frameshift, in-frame

Figure 1. Identification of recurrent pathogenic or likely pathogenic variants (using the ACMG criteria) in 20 severely ill ME/CFS patients.

Figure 2. Examining the relationship between the SIPS disease module and ME/CFS diagnostic phenotypes, as well as the underlying biological mechanisms. (A) The significance of the enrichment between the SIPS disease module, two ME/CFS underlying conditions (fatigue and cognitive disorders) and six specific neurodegenerative diseases (Prion disease, Parkinson's Disease, Alzheimer's disease, Huntington's disease, Spinocerebellar ataxia, and ALS). The bar plots show fold enrichments, and the colors show the p-values. (B) The interrelationship between the SIPS disease module and neurodegenerative disease pathways from KEGG. The intersection between these two entities is represented in yellow, with the SIPS side in red and the neurodegenerative disease side in blue.

Figure 3. The SIPS and DIAMOnD disease modules. (A) The relationship between the SIPS and 70 DIAMOnD disease modules, with diseases classified into five categories using Disease Ontology (Baron et al., 2024) for disease typing. The four categories, excluding cancer, were selected based on their potential connection to proposed mechanisms of ME/CFS. The similarity measurement is based on the Jaccard index of overlapping protein interactions. (B) The network representation of the SIPS disease modules and 70 DIAMOnD disease modules, with edges colored according to the category that used the edge most frequently.

(A)

ME/CFS consensus
ME/CFS non-SIPS
SIPS specific
Depression

(B)

Gastrin signaling pathway
VEGFA-VEGFR2 signaling
Calcium regulation in cardiac cells
Common pathways underlying drug addiction

Epstein-Barr virus infection
Antigen processing and presentation
MAPK signaling pathway
positive regulation of immune response
LARC complex

response to hormone

Cytokine Signaling in Immune system
Hepatitis C
TNF-alpha/Nf-kappa B signaling complex
Toxoplasmosis
TNF-alpha/NF-kappa B signaling complex 6

552　Figure 4. Characterization of the SIPS disease module. (A) The network representation of ME/CFS
553　disease modules, with the depression disease module added for location reference. (B) The largest
554　intra-cluster network component inferred by Metascape from the multi-gene set analysis, with terms
555　not supported by all the ME/CFS disease modules being grayed out.

559